Reuters logo
BRIEF-Atossa receives positive interim review from safety committee in Endoxifen study
April 20, 2017 / 1:07 PM / 5 months ago

BRIEF-Atossa receives positive interim review from safety committee in Endoxifen study

April 20 (Reuters) - Atossa Genetics Inc:

* Atossa Genetics receives positive interim review from independent safety committee in phase 1 Endoxifen dose escalation study

* Atossa Genetics- independent safety committee reviewed blinded data from first cohort of study, concluded that study may advance to next dosing level Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below